27 Oct 2022 07:31
Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation. With the publication of this announcement, this information is now considered to be in the public domain.
27 October 2022
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
ASTRO presentation highlights potential superiority of LIGHT over Gamma Knife, photon or cyclotron-based proton therapy systems for the treatment of brain tumours
Advanced Oncotherapy (AIM: AVO), the developer of LIGHT, the next generation proton therapy system for cancer treatment, is pleased to announce that findings of a modelling study led by the Company's research partner, the Cleveland Clinic, were presented yesterday at the American Society for Radiation Oncology ("ASTRO") 2022 Annual Meeting held in San Antonio, USA1.
The research quantitatively compared treatment plan quality from different proton systems, including LIGHT, and photon systems such as Gamma Knife radiosurgery2 for the irradiation of brain metastases. The findings support the potential of LIGHT to deliver superior results in the treatment of such tumours, as a result of the fast delivery time and precision that minimises the damage to surrounding healthy tissues.
The study detailed the treatment planning of brain metastases for 35 brain lesions from 20 patients. The researchers developed treatment plans using cyclotron and LIGHT proton systems as well as the photon systems. The study results indicated that the dose differential between radiation delivered to the tumour compared to surrounding healthy brain dose was significantly improved with the LIGHT system compared to the cyclotron and photon systems:
· Dose differential between tumour and healthy tissue is a key quality parameter for such treatment. Quantitatively, the average dose to the healthy tissue in the entire brain was reduced between 17%-44% with the LIGHT system.
· The LIGHT treatment plan enabled, on average, 58% faster dose delivery compared to the cyclotron treatment plan. This speed advantage was due to the ultra-fast energy switching time of 5 milliseconds that is uniquely possible with the LIGHT system.
Dr Jonathan Farr, Chief Clinical Officer at Advanced Oncotherapy said:
"We were pleased to present results of research led by our partner, the Cleveland Clinic, at the ASTRO conference. The modelling study shows that linear accelerator proton beams have the potential to outperform both photon-based and cyclotron-generated proton beams modalities in the treatment of small brain tumours, as their precision and fast proton delivery time minimises damage to surrounding healthy tissues.
"We believe the LIGHT system is set to be the most versatile proton therapy system available. As this modelling study shows, it is ideally positioned to deliver precisely both linear accelerator proton beams and linear accelerator proton mini-beams. In addition, it has great potential to provide cutting edge treatment protocols such as scanned, conformal FLASH radiotherapy. With our first commercial LIGHT accelerator now generating a 230MeV beam, Advanced Oncotherapy will continue to work with our research partners as we move towards treating our first patients, which we expect in the second half of 2023."
- ENDS -
Advanced Oncotherapy plc | www.avoplc.com |
Dr. Michael Sinclair, Executive Chairman | Tel: +44 (0) 20 3617 8728 |
Nicolas Serandour, CEO |
|
| |
Allenby Capital Limited (Nomad and Joint Broker) | |
Nick Athanas / Piers Shimwell (Corporate Finance) Amrit Nahal / Matt Butlin (Sales and Corporate Broking) | Tel: +44 (0) 20 3328 5656 |
SI Capital Ltd (Joint Broker) |
|
Nick Emerson | Tel: +44 (0) 1483 413 500 |
Jon Levinson | Tel: +44 (0) 20 3871 4066 |
| |
FTI Consulting (Financial PR & IR) | advancedoncotherapy@fticonsulting.com |
Simon Conway / Rob Winder | Tel: +44 (0) 20 3727 1000 |
Notes to Editors
1- American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting held in San Antonio, USA. The presentation is entitled "Can Proton Linear Accelerator Beams and Minibeams Achieve Superior Plan Quality over Cyclotron-Generated Proton Beams and Photons in the Treatment of Multiple Brain Metastases?," T. Gray, A.M. Kolano, L. Chieh-Wen, J.D. Donaghue, Y.B. Cho, J.B. Farr, P. Xia, International Journal of Radiation Oncology, Biology, Physics 114, e572-e573 (2022)
2- Gamma Knife is a focused array of photon beams for treating brain tumours
About Advanced Oncotherapy Plc
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.